O1-[(5-methylisoxazol-3-yl)carbonyl]-4-(tert-butyl)benzene-1-carbohydroximamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: O1-[(5-methylisoxazol-3-yl)carbonyl]-4-(tert-butyl)benzene-1-carbohydroximamide
• 英文别名: [(Z)-[amino-(4-tert-butylphenyl)methylidene]amino] 5-methyl-1,2-oxazole-3-carboxylate
• 化学式: C₁₆H₁₉N₃O₃
• 分子量: 301.34
• InChiKey: NSTWPGVMXNZWJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  90.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• EP2908843A1
  申请人：——

  公开号：EP2908843A1

  公开（公告）日：2015-08-26
• TREATING CANCER
  申请人：Agency for Science, Technology and Research

  公开号：EP2908843B1

  公开（公告）日：2019-09-04
• EZH2 Cancer Markers
  申请人：Chinnaiyan Arul M.

  公开号：US20090012031A1

  公开（公告）日：2009-01-08

  The present invention relates to therapeutic targets for cancer. In particular, the present invention relates to small molecules and nucleic acids that target EZH2 expression in prostate cancer.
• COMPOSITIONS AND METHODS FOR INHIBITING EZH2
  申请人：Chinnaiyan Arul M.

  公开号：US20100222420A1

  公开（公告）日：2010-09-02

  The present invention relates to therapeutic targets for cancer. In particular, the present invention relates to small molecules and nucleic acids that target EZH2 expression in prostate cancer.
• METHOD OF TREATING CANCER
  申请人：Agency for Science, Technology and Research

  公开号：US20150258175A1

  公开（公告）日：2015-09-17

  The present invention relates to a pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitor and an enhancer of interferon-gamma receptor activity. The invention also relates to method of treating a patient having cancer, comprising administration of the pharmaceutical composition.